{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:45Z","timestamp":1775872305062,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the outcomes for relapsed\/refractory diffuse large B-cell lymphoma (DLBCL). However, immune effector cell\u2013associated neurotoxicity syndrome (ICANS) remains a concern. Pre-existing neurological disorders such as Parkinson\u2019s disease (PD) introduce additional, poorly studied challenges due to the risk of unpredictable complications. We report a 62-year-old man with relapsed DLBCL and pre-existing PD who was treated with lisocabtagene maraleucel. Baseline assessments by neurology, physiotherapy, and speech-language teams enabled tailored monitoring, including use of a modified Immune Effector Cell\u2013Associated Encephalopathy (ICE) score. His dopaminergic regimen was optimised prior to therapy. Following lymphodepletion and CAR-T infusion, he experienced grade 1 cytokine release syndrome, which resolved with tocilizumab and ward-based supportive care. Although a stable partial response was observed on PET-CT scan at 1 and 3 months, the absence of ICANS or PD worsening up to his most recent follow-up on Day +86 suggests that CAR-T therapy can be safely delivered in patients with pre-existing PD when tailored strategies are applied, including a multidisciplinary approach, modified neurotoxicity monitoring, and careful selection of the CAR-T construct. Further studies and longer follow-up are needed to clarify long-term safety in this population.<\/jats:p>","DOI":"10.3389\/fonc.2026.1759390","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:37Z","timestamp":1772083777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: CAR-T therapy for relapsed diffuse large B-cell lymphoma in a patient with pre-existing Parkinson\u2019s disease\u2014unfolding clinical challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Anas","family":"Ibraheem","sequence":"first","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]},{"name":"Department of Oncology, The London Clinic","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Vincentelli","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kuhnl","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil A","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres Moya","family":"Davila","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piers EM","family":"Patten","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]},{"name":"Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Medicine, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Yallop","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]},{"name":"Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Medicine, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Graham","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]},{"name":"Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Medicine, King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Niblock","sequence":"additional","affiliation":[{"name":"Northern Health Care and Social Trust","place":["Antrim, Northern Ireland, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Sanderson","sequence":"additional","affiliation":[{"name":"Department of Haematology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101140","article-title":"A paradox of choice: Sequencing therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"63","author":"Brooks","year":"2024","journal-title":"Blood Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00970-z","article-title":"Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands","volume":"14","author":"Pennings","year":"2024","journal-title":"Blood Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S326632","article-title":"Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options","volume":"15","author":"Vodicka","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06841-6","article-title":"Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series","volume":"44","author":"Fontanelli","year":"2023","journal-title":"Neurol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1271072","article-title":"Reducing the receipt of contraindicated medications in patients with Parkinson disease","volume":"15","author":"Goldin","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2506","article-title":"Parkinsonism following chimeric antigen receptor T cell therapy","volume":"81","author":"Gudera","year":"2024","journal-title":"JAMA Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment-associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic Malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017604","article-title":"How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-333924","article-title":"Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy","volume":"96","author":"Vonberg","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e009525","DOI":"10.1136\/jitc-2024-009525","article-title":"Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapy","volume":"12","author":"Larue","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2024.04.014","article-title":"EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome","volume":"163","author":"Hernani","year":"2024","journal-title":"Clin Neurophysiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287010","article-title":"Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up","volume":"110","author":"Portuguese","year":"2025","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448709","article-title":"The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia","volume":"15","author":"Ma","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008937","article-title":"Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome","volume":"7","author":"Bhaskar","year":"2023","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e000927","DOI":"10.1136\/bmjno-2024-000927","article-title":"Monitoring the neurological complications of chimeric antigen receptor (CAR) T-cell therapy in patients with sensory and physical impairments and non-native-speaking backgrounds using modified immune effector cell-associated encephalopathy (ICE) scores: a case series","volume":"7","author":"Kazzi","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.14239","article-title":"Parkinsonism associated with anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy","volume":"11","author":"Schneider","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"B30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-020-00375-7","article-title":"Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders","volume":"15","author":"Machhi","year":"2020","journal-title":"Mol Neurodegener"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac084","article-title":"The potential for treg-enhancing therapies in nervous system pathologies","volume":"211","author":"Olson","year":"2023","journal-title":"Clin Exp Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1759390\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:38Z","timestamp":1772083778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1759390\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1759390"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1759390","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1759390"}}